Schering-Plough said regulators had rejected Bridion, its drug to reverse the effects of anesthesia that had been heralded as a breakthrough product by analysts.
The latest massive merger deal announced in the drug sector will see Merck & Co. buy Schering-Plough Co. for about $41.1 billion US in cash and stock, the companies said Monday.
GAITHERSBURG, Md. (AP) -- Federal health advisers have voted 6-4 that the potential benefits of a Schering-Plough drug used to treat late-stage skin cancer outweigh its toxic risks....
Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin because the data was unfavorable.
KENILWORTH , N.J., April 30 (UPI) -- The U.S. Food and Drug Administration rejected a proposed pill that would combine the drugs Claritin and Singular, Schering-Plough said.
... regulators are investigating whether a group of best-selling arthritis drugs made by Abbott Laboratories, Schering-Plough Corp. and other companies heighten the risk of cancer in youngsters....
Regulators are investigating whether a group of arthritis drugs made by Abbott Laboratories, Schering-Plough and other companies heighten the risk of cancer in youngsters.
... diseases."
In March 2008, Centocor Inc. and Schering-Plough Corporation (NYSE: SGP) announced that ... unique disease states. Golimumab, Centocor's and Schering-Plough's next-generation human anti-TNF ...
TRENTON, N.J. (AP) -- In the latest disappointment for cholesterol pill Vytorin, a major European study in patients with heart valve disease found the drug didn't prevent worsening of the disease ...
... Center, and Robert Pierce, currently head of anatomic pathology at Schering-Plough Biopharma Schering-Plough Biopharma and formerly of the University of Rochester Medical Center, are collaborating on ...
... . These can later be used as medicines.
Patent
The compounds developed were synthesised by the companies Schering-Plough (formerly Organon BV) and SyMO-Chem BV. The potential of the compounds was ...
... .
While Gordon Coutts, Vice President and General Manager at Schering Plough UK believes that joint working has the potential to create breakthroughs in how the UK tackles major health ...
... about their appearance.*The findings, announced today, arose from a survey of 787 people with hayfever conducted by YouGov on behalf of Schering-Plough last summer.
read more
The new drug is a follow-up to Remicade, which is marketed in the United States by Johnson & Johnson and in Europe and in other countries by the Schering-Plough Corporation.
... have received consulting fees and/or grant support from Vertex, Roche (maker of peginterferon) and Schering-Plough (maker of ribavirin).
The study's results match those of a similar study conducted ...
